MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
13. Dezember 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer
11. Dezember 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degr
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
05. Dezember 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
26. November 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
13. November 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
07. November 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
28. Oktober 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
23. Oktober 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
28. August 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences